TREA

Automatic alignment of a contrast enhancement system

Follow

Information

  • Patent Grant
  • 11847768
  • Patent Number
    11,847,768
  • Date Filed
    Thursday, September 16, 2021
    2 years ago
  • Date Issued
    Tuesday, December 19, 2023
    4 months ago
Information
Abstract
An apparatus and method for insuring the proper alignment of a detected vein pattern and a projected vein pattern are disclosed. The apparatus enhances the visual appearance of veins so that an error that can lead to improper patient care or injury can be avoided.
Description
SUMMARY OF THE INVENTION

An apparatus and method for insuring the proper alignment of a detected vein pattern and a projected vein pattern in a apparatus that enhances the visual appearance of veins so that an error that can lead to improper patient care or injury can be avoided.


BACKGROUND OF THE INVENTION

It is known in the art to use an apparatus to enhance the visual appearance of the veins and arteries in a patient to facilitate insertion of needles into those veins and arteries as well as other medical practices that require the identification of vein and artery locations. Such a system is described in U.S. Pat. Nos. 5,969,754 and 6,556,858 incorporated herein by reference as well as publication entitled “The Clinical Evaluation of Vein Contrast Enhancement”. Luminetx is currently marketing such a device under the name “Veinviewer Imaging System” and information related thereto is available on their website, which is incorporated herein by reference.


The Luminetx Vein Contrast Enhancer (hereinafter referred to as LVCE) utilizes a light source for flooding the region to be enhanced with near infrared light generated by an array of LEDs. A CCD imager is then used to capture an image of the infrared light reflected off the patient. The resulting captured image is then digitally enhanced and then projected by a visible light projector onto the patient in a position that must be closely aligned with position of the captured image. The practitioner uses this projected image to determine the position in which to insert a needle. Should the image be misaligned, the patient can be injured.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an embodiment of a vein contrast enhancer.



FIG. 2 is a representation of a patient's arm.



FIG. 3 shows an embodiment of a laser contrast enhancer.





DETAILED DESCRIPTION OF THE INVENTION

As shown in FIG. 1, a typical embodiment of a vein contrast enhancer (VCE) 100 contains a camera 101 which is used to capture an image of a patient's body 105, a processing system (not shown) that enhances the image captured by the camera to highlight the positions of veins, and a projector 102 that shows an image of the enhanced vein pattern back onto the patient's body 105. Since the camera and projector are physically separate devices they reach the patient's body from different source points along different paths 103, 104. In some embodiments, the paths are made coaxial within the body of the VCE, however at some point the paths are separate since the devices (camera and projector) are physically separate devices. Since the purpose of a VCE is to allow the practitioner to insert a needle into the highlighted vein, it is critically important that the projected image and the actual vein location be aligned. Typically this alignment is done as a separate step in the use of the VCE. A card with a known pattern is placed with the viewing/projecting field of the VCE. This card has a florescent material applied to it so that when it is struck by green light, it emits infrared light that can be seen by the camera. This image is used to align the VCE.


This invention describes methods for achieving this alignment without requiring the operator to take a separate step.


Referring to FIG. 2, a representation of the patient's arm 201 is shown along with several veins. A bounding box is shown around a single vein 200. In FIG. 3, a schematic representation of the bounded area of the single vein is shown 305. Typically, the enhancement image will light up the area around the vein and will be dark on the vein. When property aligned, the bright part of the image 300 will have edges that properly align with the edges of the vein 303, 304. As previously described, the VCE will typically have an alignment mode wherein a known pattern, typically presented on an alignment card, will be placed in front of the VCE and an alignment will be performed. This alignment can either be automatically performed by the VCE or manually performed by the operator. The weakness of this kind of implementation is that it relies on the expectation that the alignment will be maintained over time. If the alignment should shift, patient injury can occur.


In a typical VCE, an infrared light source and a camera that is sensitive only to infrared light is used to detect the vein position. Furthermore, the projected image is often green in color to insure that the light from the projector is ignored since the camera is sensitive only light near the infrared region. This selectivity can be implemented either with filters or with selectively sensitive camera elements.


Referring back to FIG. 3, in a typical LCE, the camera, by design, is blind to the projected light. In our invention, the camera is by design, able to selectively see the projected light. In a preferred embodiment, a multi-color capable projector is used. As usual, green is used to fill the area outside of the vein 300. That green projection goes to the edges of the vein position 303, 304 and the vein area itself is left dark. A camera that is sensitive to red and infrared light is used in this embodiment. In addition to the green fill, red lines are drawn at the edges of the veins 303, 304. Since the camera can see these red lines, the image enhancement software can look to see if the red lines are at the proper position and if needed automatic alignment can be performed. An alternative embodiment would be to paint a red line 306 down the middle of the vein position. An alternative embodiment would be to paint some pattern of red light over a desired, portion of the vein.


Typically the cameras used in an LCE are monochrome and unable to discriminate between light of different wavelengths. Depending on the sensitivity of the camera and the brightness of the projector compared to the infrared flood lighting provided by the LCE, various techniques can be used to aid the camera in the detection of the red lines. One method is to simply look for the brightening caused by the addition of the red lines to the reflected infrared light. A second method is to periodically turn off the infrared lighting such that only ambient infrared and the projected red are seen by the camera. This can make it easier for the system to detect the red lines.


Although we've described the invention using red and green lights, various combinations of colors can be used. Red and infrared light are known in the art to be useful for vein detection. Any combinations of colors of shorter wavelengths can be used for projection and alignment images as long as the camera selected is properly selected or filtered to achieve the desired discrimination between wavelengths. Furthermore, while discrimination between projection, detection and alignment signals in the preferred embodiment has been described using different wavelengths to separate the signals, in an embodiment with less freedom of projected color, time division can be used where the projected image is shown most of the time and the alignment image is shown interspersed on a lower duty cycle basis. Properly implemented, the alignment image will be quite visible to the VCE's camera, but invisible to the operator of the VCE.


Projectors in VCEs can be either monochrome (e.g., projecting green only) or multicolor (e.g., projecting RGB). The advantage of a monochrome implementation is that since an array of single color LEDs can be used in place of white bulbs and a color wheel typically found in a multicolor projector the system can be of lower cost, generate loss heat and have higher reliability. In such an embodiment, the time division scheme describe above would be appropriate. In tins monochrome configuration, an alternative embodiment would be to add a smaller array of a second color of LEDs (i.e., red). This alignment array can be smaller than the projection array in that it doesn't need to be visible to the operator, just to the camera. The projection LEDs and the alignment LEDs could then be time multiplexed as previously described.

Claims
  • 1. A vein imaging system comprising: means for illuminating a field of view with a first wavelength of light comprising an infrared wavelength, thereby creating an image contrast of one or more veins formed by differential amounts of absorption and reflection of said first wavelength of light by the one or more veins and surrounding tissue in the field of view;an alignment card comprising a pattern formed of a material that emits a second wavelength of light when exposed to a third wavelength of light;means for capturing said image contrast of the one or more veins at said first wavelength of light;a projector configured to receive and to project said captured image contrast onto the field of view using said third wavelength of light;wherein said means for capturing is further configured for capturing said second wavelength of light emitted by said pattern when positioned in the field of view, and for capturing said third wavelength of light reflected from said pattern, said means for capturing further configured for distinguishing said third wavelength of light reflected by said pattern from said second wavelength of light emitted by said pattern; andwherein said means for capturing is further configured for aligning said projecting of said captured image contrast with said image contrast formed by the differential absorption and reflection, using said distinction between said captured reflection of said pattern at said third wavelength of light and said captured emission from said pattern at said second wavelength of light.
  • 2. The vein imaging system according to claim 1 wherein said pattern comprises a fluorescent material.
  • 3. The system according to claim 1 wherein said pattern comprises a known pattern.
  • 4. The vein imaging system according to claim 1 wherein said third wavelength of light comprises a human visible wavelength of light.
  • 5. The vein imaging system according to claim 1 wherein said third wavelength of light comprises a green wavelength of light.
  • 6. The vein imaging system according to claim 5 wherein said second wavelength of light comprises a red wavelength of light.
  • 7. The vein imaging system according to claim 6 wherein said green wavelength of light of said projected image contrast is projected onto the field of view outside of the one or more veins.
  • 8. The vein imaging system according to claim 1 wherein said third wavelength of light and said infrared first wavelength of light are alternately projected and illuminated, respectively.
  • 9. The vein imaging system according to claim 8 wherein said third wavelength of light is projected at a higher duty cycle than said illumination with said infrared wavelength.
  • 10. The vein imaging system according to claim 1 wherein said projector is further configured to project a line along the middle of each of the one or more veins.
  • 11. A vein imaging system comprising: a light source configured to illuminate a field of view with a first wavelength of light, said first wavelength comprising an infrared wavelength that creates an image contrast of one or more veins formed by differential amounts of absorption and reflection of said first wavelength of light by the one or more veins and surrounding tissue in the field of view;means for capturing said image contrast of the one or more veins at said first wavelength of light;means for receiving said captured image contrast, for projecting lines at an edge of each of the one or more veins in said captured image contrast with a second wavelength of light, for projecting said captured image contrast onto the field of view using a third wavelength of light, for capturing said projected edge lines at said second wavelength of light reflected from the field of view, for distinguishing said captured edge lines at said second wavelength of light from the edge of each of the one or more veins in said contrasted image at said first wavelength of light, and for aligning said projection of said image contrast and said edge lines at said second wavelength with said reflected edge lines of the one or more veins.
  • 12. The vein imaging system according to claim 11 wherein said second wavelength of light and said infrared first wavelength of light are alternately projected and illuminated.
  • 13. The vein imaging system according to claim 11 wherein said projected third wavelength of light is projected at a higher duty cycle than said illumination of said infrared wavelength.
  • 14. The vein imaging system according to claim 11 wherein said second wavelength of light comprises a human-visible red wavelength of light.
  • 15. The vein imaging system according to claim 11 wherein said third wavelength of light comprises a green wavelength of light.
CROSS REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/909,093, filed Jun. 23, 2020, which is a continuation of U.S. patent application Ser. No. 16/741,859, filed Jan. 14, 2020, now issued as U.S. Pat. No. 10,713,766, which is a continuation of U.S. patent application Ser. No. 16/121,668, filed Sep. 9, 2018, now issued as U.S. Pat. No. 10,580,119, which is a continuation of U.S. application patent Ser. No. 15/665,504, filed Aug. 1, 2017, now issued as U.S. Pat. No. 10,096,096, which is a continuation of U.S. patent application Ser. No. 15/226,027, filed Aug. 2, 2016, now issued as U.S. Pat. No. 9,760,982, which is a continuation of U.S. patent application Ser. No. 14/196,172, filed Mar. 4, 2014, now issued as U.S. Pat. No. 9,430,819, which is a continuation of U.S. patent application Ser. No. 12/215,713, filed Jun. 27, 2008, now issued as U.S. Pat. No. 8,730,321, which claims priority on U.S. Provisional Application Ser. No. 60/937,618, filed Jun. 28, 2007, all disclosures of which are incorporated herein by reference.

US Referenced Citations (301)
Number Name Date Kind
3136310 Meltzer Jun 1964 A
3349762 Kapany Oct 1967 A
3511227 Johnson May 1970 A
3527932 Thomas Sep 1970 A
3818129 Yamamoto Jun 1974 A
3984629 Gorog Oct 1976 A
4030209 Dreiding Jun 1977 A
4057784 Tafoya Nov 1977 A
4109647 Stem et al. Aug 1978 A
4162405 Chance et al. Jul 1979 A
4182322 Miller Jan 1980 A
4185808 Donohoe et al. Jan 1980 A
4213678 Pomerantzeff et al. Jul 1980 A
4265227 Ruge May 1981 A
4312357 Andersson et al. Jan 1982 A
4315318 Kato et al. Feb 1982 A
4321930 Jobsis et al. Mar 1982 A
4393366 Hill Jul 1983 A
4495949 Stoller Jan 1985 A
4502075 DeForest et al. Feb 1985 A
4510938 Jobsis et al. Apr 1985 A
4536790 Kruger et al. Aug 1985 A
4565968 Macovski Jan 1986 A
4567896 Barnea et al. Feb 1986 A
4576175 Epstein Mar 1986 A
4590948 Nilsson Mar 1986 A
4586190 Tsuji Apr 1986 A
4596254 Adrian et al. Jun 1986 A
4619249 Landry Oct 1986 A
4669467 Willett et al. Jun 1987 A
4697147 Moran et al. Sep 1987 A
4699149 Rice Oct 1987 A
4703758 Omura Nov 1987 A
4766299 Tierney et al. Aug 1988 A
4771308 Tejima et al. Sep 1988 A
4780919 Harrison Nov 1988 A
4799103 Muckerheide Jan 1989 A
4817622 Pennypacker et al. Apr 1989 A
4846183 Martin Jul 1989 A
4861973 Hellekson et al. Aug 1989 A
4862894 Fujii Sep 1989 A
4899756 Sonek Feb 1990 A
4901019 Wedeen Feb 1990 A
4926867 Kanda et al. May 1990 A
RE33234 Landry Jun 1990 E
4938205 Nudelman Jul 1990 A
5074642 Hicks Dec 1991 A
5088493 Giannini et al. Feb 1992 A
5103497 Hicks Apr 1992 A
5146923 Dhawan Sep 1992 A
5174298 Dolfi et al. Dec 1992 A
5184188 Bull et al. Feb 1993 A
5214458 Kanai May 1993 A
5222495 Clarke et al. Jun 1993 A
5261581 Harden, Sr. Nov 1993 A
5293873 Fang Mar 1994 A
5339817 Nilsson Aug 1994 A
5371347 Plesko Dec 1994 A
5406070 Edgar et al. Apr 1995 A
5418546 Nakagakiuchi et al. May 1995 A
5423091 Lange Jun 1995 A
5436655 Hiyama et al. Jul 1995 A
5445157 Adachi et al. Aug 1995 A
D362910 Creaghan Oct 1995 S
5485530 Lakowicz et al. Jan 1996 A
5487740 Sulek et al. Jan 1996 A
5494032 Robinson et al. Feb 1996 A
5497769 Gratton et al. Mar 1996 A
5501680 Kurtz Mar 1996 A
5504316 Bridgelall et al. Apr 1996 A
5519208 Esparza et al. May 1996 A
5541820 McLaughlin Jul 1996 A
5542421 Erdman Aug 1996 A
5598842 Ishihara et al. Feb 1997 A
5603328 Zucker et al. Feb 1997 A
5608210 Esparza Mar 1997 A
5610387 Bard et al. Mar 1997 A
5625458 Alfano et al. Apr 1997 A
5631976 Bolle et al. May 1997 A
5655530 Messerschmidt Aug 1997 A
5678555 O'Connell Oct 1997 A
5716796 Bull et al. Feb 1998 A
5719399 Alfano et al. Feb 1998 A
5740801 Branson Apr 1998 A
5747789 Godik May 1998 A
5756981 Roustaei et al. May 1998 A
5758650 Miller et al. Jun 1998 A
5772593 Hakamata Jun 1998 A
5787185 Clayden Jul 1998 A
5814040 Nelson et al. Sep 1998 A
5836877 Zavislan Nov 1998 A
5847394 Alfano et al. Dec 1998 A
5860967 Zavislan et al. Jan 1999 A
5865828 Jeng Feb 1999 A
5929443 Alfano et al. Jul 1999 A
5946220 Lemelson Aug 1999 A
5947906 Dawson, Jr. et al. Sep 1999 A
5966204 Abe Oct 1999 A
5966230 Swartz et al. Oct 1999 A
5969754 Zeman Oct 1999 A
5982553 Bloom et al. Nov 1999 A
5988817 Mizushima et al. Nov 1999 A
5995856 Mannheimer et al. Nov 1999 A
5995866 Lemelson Nov 1999 A
6006126 Cosman Dec 1999 A
6032070 Flock et al. Feb 2000 A
6056692 Schwartz May 2000 A
6061583 Ishihara et al. May 2000 A
6083486 Weissleder et al. Jul 2000 A
6101036 Bloom Aug 2000 A
6113536 Aboul-Hosn et al. Sep 2000 A
6122042 Wunderman et al. Sep 2000 A
6132379 Patacsil et al. Oct 2000 A
6135599 Fang Oct 2000 A
6141985 Cluzeau et al. Nov 2000 A
6142650 Brown et al. Nov 2000 A
6149061 Massieu et al. Nov 2000 A
6149644 Xie Nov 2000 A
6171301 Nelson et al. Jan 2001 B1
6178340 Svetliza Jan 2001 B1
6179260 Ohanian Jan 2001 B1
6230046 Crane et al. May 2001 B1
6240309 Yamashita et al. May 2001 B1
6251073 Imran et al. Jun 2001 B1
6263227 Boggett et al. Jul 2001 B1
6272376 Marcu et al. Aug 2001 B1
6301375 Choi Oct 2001 B1
6305804 Rice et al. Oct 2001 B1
6314311 Williams et al. Nov 2001 B1
6334850 Amano et al. Jan 2002 B1
6353753 Flock et al. Mar 2002 B1
6424858 Williams Jul 2002 B1
6436655 Bull et al. Aug 2002 B1
6438396 Cook et al. Aug 2002 B1
6463309 Ilia Oct 2002 B1
6464646 Shalom et al. Oct 2002 B1
6523955 Eberl et al. Feb 2003 B1
6542246 Toida Apr 2003 B1
6556854 Sato et al. Apr 2003 B1
6556858 Zeman Apr 2003 B1
6599247 Stetten Jul 2003 B1
6631286 Pfeiffer et al. Oct 2003 B2
6648227 Swartz et al. Nov 2003 B2
6650916 Cook et al. Nov 2003 B2
6689075 West Feb 2004 B2
6690964 Bieger et al. Feb 2004 B2
6702749 Paladini et al. Mar 2004 B2
6719257 Greene et al. Apr 2004 B1
6755789 Stringer et al. Jun 2004 B2
6777199 Bull et al. Aug 2004 B2
6782161 Barolet et al. Aug 2004 B2
6845190 Smithwick et al. Jan 2005 B1
6882875 Crowley Apr 2005 B1
6889075 Marchitto et al. May 2005 B2
6913202 Tsikos et al. Jul 2005 B2
6923762 Creaghan, Jr. Aug 2005 B1
6971579 Barkan Dec 2005 B2
6980852 Jersey-Willuhn et al. Dec 2005 B2
7092087 Kumar et al. Aug 2006 B2
7113817 Winchester, Jr. et al. Sep 2006 B1
7158660 Gee, Jr. et al. Jan 2007 B2
7158859 Wang et al. Jan 2007 B2
7204424 Yavid et al. Apr 2007 B2
7225005 Kaufman et al. May 2007 B2
7227611 Hull et al. Jun 2007 B2
7239909 Zeman Jul 2007 B2
7247832 Webb Jul 2007 B2
7280860 Ikeda et al. Oct 2007 B2
7283181 Allen et al. Oct 2007 B2
7302174 Tan et al. Nov 2007 B2
7333213 Kempe Feb 2008 B2
D566283 Brafford et al. Apr 2008 S
7359531 Endoh et al. Apr 2008 B2
7376456 Marshik-Geurts et al. May 2008 B2
7428997 Wiklof et al. Sep 2008 B2
7431695 Creaghan Oct 2008 B1
7448995 Wiklof et al. Nov 2008 B2
7532746 Marcotte et al. May 2009 B2
7545837 Oka Jun 2009 B2
7559895 Stetten et al. Jul 2009 B2
7579592 Kaushal Aug 2009 B2
7608057 Woehr et al. Oct 2009 B2
7699776 Walker et al. Apr 2010 B2
7708695 Akkermans et al. May 2010 B2
7791561 Hajjar Sep 2010 B2
7792334 Cohen et al. Sep 2010 B2
7846103 Cannon, Jr. et al. Dec 2010 B2
7848103 Zhan Dec 2010 B2
7904138 Goldman et al. Mar 2011 B2
7904139 Chance Mar 2011 B2
7925332 Crane et al. Apr 2011 B2
7966051 Xie et al. Jun 2011 B2
8032205 Mullani Oct 2011 B2
8078263 Zeman et al. Dec 2011 B2
8187189 Jung et al. May 2012 B2
8199189 Kagenow et al. Jun 2012 B2
8320998 Sato Nov 2012 B2
8336839 Boccoleri et al. Dec 2012 B2
8364246 Thierman Jan 2013 B2
8467855 Yasui Jun 2013 B2
8480662 Stolen et al. Jul 2013 B2
8494616 Zeman Jul 2013 B2
8498694 McGuire, Jr. et al. Jul 2013 B2
8509495 Xu et al. Aug 2013 B2
8537203 Seibel et al. Sep 2013 B2
8548572 Crane Oct 2013 B2
8630465 Wieringa et al. Jan 2014 B2
8649848 Crane et al. Feb 2014 B2
10580119 Luciano Mar 2020 B2
10713766 Luciano Jul 2020 B2
11132774 Luciano Sep 2021 B2
20010006426 Son et al. Jul 2001 A1
20010056237 Cane et al. Dec 2001 A1
20020016533 Marchitto et al. Feb 2002 A1
20020118338 Kohayakawa Aug 2002 A1
20020188203 Smith et al. Dec 2002 A1
20030018271 Kimble Jan 2003 A1
20030037375 Riley et al. Feb 2003 A1
20030047683 Kaushal Mar 2003 A1
20030052105 Nagano et al. Mar 2003 A1
20030120154 Sauer et al. Jun 2003 A1
20030125629 Ustuner Jul 2003 A1
20030156260 Putilin et al. Aug 2003 A1
20040015062 Ntziachristos et al. Jan 2004 A1
20040015158 Chen et al. Jan 2004 A1
20040022421 Endoh et al. Feb 2004 A1
20040046031 Knowles et al. Mar 2004 A1
20040171923 Kalafut et al. Sep 2004 A1
20040222301 Willins et al. Nov 2004 A1
20040237051 Clauson Nov 2004 A1
20050003323 Katsuda Jan 2005 A1
20050017924 Utt et al. Jan 2005 A1
20050023356 Wiklof Feb 2005 A1
20050033145 Graham et al. Feb 2005 A1
20050043596 Chance Feb 2005 A1
20050047134 Mueller et al. Mar 2005 A1
20050085732 Sevick-Muraca et al. Apr 2005 A1
20050085802 Gruzdev et al. Apr 2005 A1
20050113650 Pacione et al. May 2005 A1
20050131291 Floyd et al. Jun 2005 A1
20050135102 Gardiner et al. Jun 2005 A1
20050141069 Wood et al. Jun 2005 A1
20050143662 Marchitto et al. Jun 2005 A1
20050146765 Turner et al. Jul 2005 A1
20050154303 Walker et al. Jul 2005 A1
20050157939 Arsenault et al. Jul 2005 A1
20050161051 Pankratov et al. Jul 2005 A1
20050168980 Dryden et al. Aug 2005 A1
20050174777 Cooper et al. Aug 2005 A1
20050175048 Stern et al. Aug 2005 A1
20050187477 Serov et al. Aug 2005 A1
20050215875 Khou Sep 2005 A1
20050265586 Rowe et al. Dec 2005 A1
20050281445 Marcotte et al. Dec 2005 A1
20060007134 Ting Jan 2006 A1
20060020212 Xu et al. Jan 2006 A1
20060025679 Viswanathan et al. Feb 2006 A1
20060052690 Sirohey et al. Mar 2006 A1
20060081252 Wood Apr 2006 A1
20060100523 Ogle et al. May 2006 A1
20060103811 May et al. May 2006 A1
20060122515 Zeman Jun 2006 A1
20060129037 Kaufman et al. Jun 2006 A1
20060129038 Zelenchuk et al. Jun 2006 A1
20060151449 Warner, Jr. et al. Jul 2006 A1
20060173351 Marcotte et al. Aug 2006 A1
20060184040 Keller et al. Aug 2006 A1
20060206027 Malone Sep 2006 A1
20060232660 Nakajima et al. Oct 2006 A1
20060247514 Panasyuk Nov 2006 A1
20060253010 Brady et al. Nov 2006 A1
20060271028 Altshuler et al. Nov 2006 A1
20060276712 Stothers Dec 2006 A1
20070015980 Numada et al. Jan 2007 A1
20070016079 Freeman et al. Jan 2007 A1
20070070302 Govorkov et al. Mar 2007 A1
20070115435 Rosendaal May 2007 A1
20070129634 Hickey et al. Jun 2007 A1
20070176851 Willey et al. Aug 2007 A1
20070225582 Diab Sep 2007 A1
20070238957 Yared Oct 2007 A1
20080039701 Ali Feb 2008 A1
20080045841 Wood et al. Feb 2008 A1
20080147147 Griffiths Jun 2008 A1
20080194930 Harris et al. Aug 2008 A1
20080214940 Benaron Sep 2008 A1
20090018414 Toofan Jan 2009 A1
20090028461 Wieringa Jan 2009 A1
20090082629 Dotan Mar 2009 A1
20090171205 Kharin et al. Jul 2009 A1
20100020078 Shpunt Jan 2010 A1
20100051808 Zeman et al. Mar 2010 A1
20100061598 Seo Mar 2010 A1
20100087787 Woehr et al. Apr 2010 A1
20100177184 Berryhill Jul 2010 A1
20100312120 Meier Dec 2010 A1
20110275932 Leblond et al. Nov 2011 A1
20130147916 Bennett et al. Jun 2013 A1
20140039309 Harris et al. Feb 2014 A1
20140046291 Harris et al. Feb 2014 A1
20140194747 Kruglick Jul 2014 A1
Foreign Referenced Citations (22)
Number Date Country
2289149 May 1976 FR
1298707 Dec 1972 GB
1507329 Apr 1978 GB
S60-108043 Jun 1985 JP
04-042944 Feb 1992 JP
07-255847 Oct 1995 JP
08-023501 Jan 1996 JP
08-164123 Jun 1996 JP
2000-316866 Nov 2000 JP
2002-328428 Nov 2002 JP
2002-345953 Dec 2002 JP
2004-237051 Aug 2004 JP
2004-329786 Nov 2004 JP
2003-0020152 Mar 2003 KR
WO 1994 22370 Oct 1994 WO
WO 1996 39925 Dec 1996 WO
WO 1998 26583 Jun 1998 WO
WO 1999 48420 Sep 1999 WO
WO 2001-82786 Nov 2001 WO
WO 2003-009750 Feb 2003 WO
WO 2005-053773 Jun 2005 WO
WO 2007-078447 Jul 2007 WO
Non-Patent Literature Citations (5)
Entry
Wiklof, Chris, “Display Technology Spawns Laser Camera,” LaserFocusWorld, Dec. 1, 2004, vol. 40, Issue 12, PennWell Corp., USA.
Nikbin, Darius, “IPMS Targets Colour Laser Projectors,” Optics & Laser Europe, Mar. 1006, Isue 137, p. 11.
http://sciencegeekgirl.wordpress.com/category/science-myths/page/2/ Myth 7: Blood is Blue.
http://www.exploratorium.edu/sports/hnds_up/hands6.html “Hands Up! To Do & Notice: Getting the Feel of Your Hand”.
http://www.wikihow.com/See-Blook-Veins-in-Your-Hand-With-a- Flashlight “How to See Blood Veins in Your Hand With a Flashlight”.
Related Publications (1)
Number Date Country
20220067892 A1 Mar 2022 US
Provisional Applications (1)
Number Date Country
60937618 Jun 2007 US
Continuations (7)
Number Date Country
Parent 16909093 Jun 2020 US
Child 17476731 US
Parent 16741859 Jan 2020 US
Child 16909093 US
Parent 16121668 Sep 2018 US
Child 16741859 US
Parent 15665504 Aug 2017 US
Child 16121668 US
Parent 15226027 Aug 2016 US
Child 15665504 US
Parent 14196172 Mar 2014 US
Child 15226027 US
Parent 12215713 Jun 2008 US
Child 14196172 US